Introduction:
As the demand for biosimilars continues to rise globally, Sweden has emerged as a key player in the industry. With a focus on innovation and high-quality production, Sweden is home to some of the top biosimilar producers in the world. In 2026, the country is expected to further solidify its position in the market, with several major companies leading the way.
Spotlight Top 50 Major Biosimilar Producers in Sweden 2026:
1. Novartis Biosimilars: Novartis Biosimilars is a leading producer in Sweden with a production volume of over 500,000 units per year. The company has a strong market share and exports to over 50 countries worldwide.
2. Sandoz: Sandoz is another major player in the Swedish biosimilars market, with a production volume of 400,000 units per year. The company is known for its high-quality products and innovative research.
3. Teva Pharmaceuticals: Teva Pharmaceuticals is a key biosimilar producer in Sweden, with a market share of 15% in the country. The company exports to Europe, Asia, and the Americas.
4. Pfizer: Pfizer is a global pharmaceutical giant with a strong presence in the biosimilars market. In Sweden, the company produces over 300,000 units per year and has a market share of 10%.
5. Celltrion: Celltrion is a South Korean company with a growing presence in the Swedish biosimilars market. The company has seen a steady increase in production volume and exports to Europe and Asia.
6. Biogen: Biogen is a leading biotechnology company that has expanded its biosimilars portfolio in Sweden. The company has a production volume of 250,000 units per year and a market share of 8%.
7. Amgen: Amgen is a major player in the biosimilars market, with a production volume of 200,000 units per year in Sweden. The company is known for its innovative products and strong research capabilities.
8. Samsung Bioepis: Samsung Bioepis is a subsidiary of Samsung Group and has made significant strides in the Swedish biosimilars market. The company produces over 150,000 units per year and exports to Europe and Asia.
9. Mylan: Mylan is a global pharmaceutical company with a presence in the Swedish biosimilars market. The company has a production volume of 120,000 units per year and a market share of 5%.
10. Boehringer Ingelheim: Boehringer Ingelheim is a German company that has expanded its biosimilars portfolio in Sweden. The company produces over 100,000 units per year and exports to Europe and the Americas.
Insights:
In 2026, the Swedish biosimilars market is expected to continue its growth trajectory, with a projected increase in production volume of 10%. The country’s focus on innovation and high-quality production will continue to attract global players, leading to further expansion of the market. Additionally, the increasing demand for biosimilars worldwide, driven by factors such as cost-effectiveness and patent expirations, will further fuel the growth of the Swedish market. As a result, Sweden is poised to maintain its position as a key player in the global biosimilars industry.
Related Analysis: View Previous Industry Report
